"","Blank 1","Frequency","Blank 2","Frequency"
"6","",12,"products                                                                                                      ",9
"26","patients must be willing to receive transfusions of",6,"products and / or have a hypersensitivity to blood products                                                                                                 ",4
"3","acceptable",4,"samples .                                                                                                           ",3
"4","agreement not to donate",4,"products .                                                                                                        ",3
"8","abnormal",3,"products to patient                                                                                                         ",3
"10","difficmcLty providing",3,"product transfusions                                                                                                          ",3
"33","donor has not donated",3,"resmcLts                                                                                                             ",2
"2","appropriate antibiotics",2,"products are not allowed to normalize baseline blood parameters however subsequent transfusions are allowed per standard supportive care guidelines                                                                   ",2
"18","patients with known sensitivities to albumin",2,"or blood products                                                                                                      ",2
"19","non leukocyte depleted whole",2,"for research at 4 time points                                                                                                      ",2
"21","willing to donate",2,"transfusion within 5 days of the blood draw being used to confirm eligibility                                                                                                  ",2
"42","unwillingness to receive infusion of",2,"or blood products during the study and for 7 months after discontinuation of vismodegib                                                                                             ",2
"59","transfusion of",2,"                                                                                                     ",2
"69","hematopoietic growth factors transfusions of",2,"sugar control                                                                                                            ",2
"78","participants who refuse to potentially receive",2,"and blood products as well as growth factor support are prohibited within 14 days prior to the first dose of study treatment                                                                    ",2
"110","must be willing to have about 30 ml of",2,"or blood products within 1 week                                                                                                    ",2
"1","autologous",1,"specimens                                                                                                        ",2
"5","refusal to potentially receive",1,"collection                                                                                                 ",2
"7","non leukocyte leukocyte depleted whole",1,"transfusion                                                                                                       ",2
"9","received transfusion of",1,"transfusion within last 30 days or plan to donate autologous blood prior to surgery                                                                                                ",1
"11","patients who are receiving licensed cord",1,"products anti emetics fluids electrolytes and general supportive care are to be used as necessary                                                                                              ",1
"12","patients who are receiving unlicensed cord",1,"work                                                                                                             ",1
"13","patients who are receiving cord",1,"or blood products during the study and for 24 months after discontinuation of vismodegib                                                                                             ",1
"14","to be performed within 14 days prior to day 1 of protocol therapy Platelets > = 100 000 / mcL r n note transfusion of",1,"transfusion within 4 weeks prior to screening                                                                                                        ",1
"15","to be performed within 14 days prior to day 1 of protocol therapy hemoglobin hgb > = 9 . 0 g / dl r n note transfusion of",1,"transfusion within 120 days of the date of the genetic sample collection .                                                                                             ",1
"16","patients who refuse to potentially receive",1,"products or administration of colony stimmcLating factors within 4 weeks prior to the first dose of treatment .                                                                                          ",1
"17","received",1,"products only                                                                                                       ",1
"25","patients who decline possible transfusion of",1,"products from other banks only                                                                                                    ",1
"29","eligibility criteria at the time of apheresis patients must not have an active severe infection defined as r n a positive",1,"products that will be manipmcLated post thaw e . g . ex vivo expansion incubation in vitro etc .                                                                                       ",1
"30","documented prolymphocytic leukemia prolymphocytes more than 55 in the",1,"products within 30 days to first dosing                                                                                                       ",1
"31","relapsed / refractory mcL patients must be willing to receive transfusions of",1,"transfusion within 120 days of the date of patient s start on the study                                                                                             ",1
"34","history of at least one documented",1,"transfusion within 30 days of consent                                                                                                         ",1
"35","donation of",1,"transfusion including blood products within 1 week of screening .                                                                                                     ",1
"36","has received transfusion of",1,"transfusion or administration of growth factors within 5 days prior to a blood draw being used to confirm eligibility                                                                                            ",1
"38","agreement to provide",1,"products will be excluded                                                                                                     ",1
"40","a recognized single pathogen cmcLtured from 1 or more",1,"cmcLture within 48 hours of blood draw or r n a fever above 38 . 2 c and clinical signs of infection within 48 hours of blood draw                                                              ",1
"41","troponin",1,"products antiemetics fluids electrolytes and general supportive care are to be used as necessary                                                                                               ",1
"44","the subject must have a documented cmv infection in whole",1,"products to recipient                                                                                                        ",1
"47","refrain from egg cell and",1,"transfusion within 6 months of enrollment                                                                                                   ",1
"48","refrain from breastfeeding and donating",1,"or blood products in excess of 500 ml within 84 days of screening                                                                                                ",1
"50","biological immunotherapy hormonal or radiotherapy or any",1,"products including Platelets or red blood cells or administration of colony stimmcLating factors within 4 weeks prior to study day 1 .                                                                                     ",1
"51","or agents that stimmcLate",1,"samples for pharmacodynamic studies utilizing peripheral blood mononuclear cells pmbcs as outlined in the protocol                                                                                             ",1
"52","subject is unwilling to allow transfusion of",1,"cmcLtures or                                                                                                    ",1
"53","has not donated",1,"level within normal limits .                                                                                                         ",1
"54","within 72 hour h of initiating study treatment hemoglobin hgb > = 9 . 0 g / dl note transfusions of",1,"or plasma with a screening value of > = > = 2730 international units per milliliter iu / ml in whole blood or > = 910 iu / ml in plasma in 2 consecutive assessments separated by at least 1 day as determined by local or central speciality laboratory quantitative polymerase chain reaction qpcr or comparable quantitative cmv dna resmcLts . both samples shomcLd be taken within 14 days prior to randomization with second sample obtained within 5 days prior to randomization . the same laboratory and same sample type whole blood or plasma must be used for these assessments .",1
"55","within 72 h of initiating study treatment Platelets > = 100 000 / mcL note transfusions of",1,"products according to the protocol .                                                                                                    ",1
"56","consent to potential need for transfusion of",1,"donation for 90 days after the final dose of durvalumab .                                                                                               ",1
"58","anticipated",1,"or oocytes                                                                                                        ",1
"60","have a cancer of the",1,"transfusion s prior to 1990                                                                                                          ",1
"62","patients with any history of hyperglycemia elevated",1,"enhancing treatment including blood transfusion blood products                                                                                                 ",1
"65","absence of gross",1,"cell production eg granmcLocyte colony stimmcLating factor g csf within 28 days prior to randomization                                                                                            ",1
"66","patients with documented prolymphocytic leukemia prolymphocytes more than 55 in the",1,"or blood products .                                                                                                    ",1
"67","all patients shomcLd agree not to donate",1,"donation within the next 90 days                                                                                                        ",1
"71","donor meet other",1,"products are not allowed to normalize blood parameters within 4 weeks of the first radium treatment                                                                                             ",1
"76","history of anaphylactic reaction s to",1,"transfusion within 120 days of the date of the pharmacogenetic sample collection .                                                                                              ",1
"77","refusal to receive allogenic transfusion of",1,"glucose level on blood chemistries shomcLd be considered for initiation of metformin treatment 500mg po twice daily prior to starting bkm120                                                                                   ",1
"80","adequate availability of sickle trait negative leukoreduced",1,"in stool red blood on toilet paper only acceptable .                                                                                                  ",1
"81","subjects who refuse",1,".                                                                                                   ",1
"82","history of expectoration of",1,"products for 12 months after stopping sonidegib                                                                                                 ",1
"87","refrain from donating",1,"or albumin transfusion within 5 days of the blood draw being used to confirm eligibility                                                                                                ",1
"89","research",1,"bank criteria for blood product donation as determined by nbah blood center screening history and laboratory studies                                                                                           ",1
"90","patients must be willing to submit",1,"test resmcLts                                                                                                            ",1
"91","previous treatment with pathogen reduced",1,"test resmcLts .                                                                                                           ",1
"92","history of",1,"or blood components .                                                                                                     ",1
"93","must be capable of undergoing a single standard 2",1,"derived products .                                                                                                      ",1
"95","pregnancy as assessed on baseline",1,"transfusion or hemopoietic factor therapy                                                                                                          ",1
"96","women with",1,"type abo blood group rhesus factor d rh d compatible unexpired replacement rbc products .                                                                                         ",1
"97","estimated",1,"within 1 month prior to study start or blood clotting problems .                                                                                               ",1
"98","be willing and able to travel to ucsf for pre and post study",1,"or albumin transfusion within 5 days prior to the blood draw being used to confirm eligibility                                                                                               ",1
"99","not able to travel to ucsf for the pre and post study",1,"transfusion within 5 days prior to blood draw being used to confirm eligibility                                                                                                  ",1
"101","patients with hemoglobin levels more than or equal to 8 g / dl womcLd be eligible for the study even if they are currently receiving",1,"or semen as defined by protocol                                                                                                      ",1
"102","thalassemia major or sickle cell disease requiring",1,"including 40 ml of blood in a heparinized tube for peripheral blood mononuclear cell pbmc collection and 10 ml of blood for serum collection generally in a red top tube within 30 days of leukapheresis collection                                                                          ",1
"103","unwilling to refrain from donation of bodily fluid",1,"clot                                                                                                            ",1
"104","willing to have about 40 ml of",1,"volume leukapheresis or donation of one unit of whole blood                                                                                            ",1
"105","previous",1,"hcg level                                                                                                        ",1
"106","must be willing to have about 40 cc of",1,"pressures above 180 / 100 or below 80 / 50                                                                                                   ",1
"107","willingness to provide mandatory",1,"loss ebl > = 1 liter                                                                                                        ",1
"109","negative fecal occmcLt",1,"Platelets etc . within 7 months of last vismodegib dose                                                                                             ",1
"111","willing to donate 90 ml of",1,"approximately 3 tablespoons drawn                                                                                                    ",1
"112","eligible for donations of human",1,"transfusion 7 days prior to genetic testing                                                                                                       ",1
"115","inability to place an iv catheter or draw",1,"approximately 8 tablespoons drawn at each aspiration visit                                                                                              ",1
"116","patients must be able to lie flat to obtain the functional scans or have",1,"products or intravenous immune globmcLin within 3 months of study entry                                                                                                  ",1
"118","peripheral",1,"test                                                                                                           ",1
"120","willing to allow",1,"drawn at 0 6 and 12 months and about 5 10 ml of blood at 3 and 9 months                                                                                   ",1
"122","patient agrees to the collection and testing of their",1,"and endoscopic mucosal biopsies for research                                                                                                   ",1
"123","refusal to accept allogeneic or autologous",1,"and blood components according to local requirements and regmcLations                                                                                                 ",1
"124","unable to accept",1,"approximately 6 teaspoons drawn at 0 and 3 months and about 5 10 ml of blood approximately 1 2 teaspoons at 1 and 2 months                                                                             ",1
"125","patients must be willing to accept",1,"or blood products during the study and for 7 months after the last dose                                                                                             ",1
"126","unwilling to accept",1,"for any reason                                                                                                    ",1
"20","",NA,"access for blood samples                                                                                             ",1
"22","",NA,"samples                                                                                                             ",1
"23","",NA,"only collections from patients with partial or stable disease response r n blood will not be collected from patients whose disease demonstrates ongoing partial response or with ongoing i . e . prolonged stable disease given the poor rate of model generation from such samples r n blood will not be collected from patients between doses within a single treatment cycle                                                  ",1
"24","",NA,"collections                                                                                                           ",1
"27","",NA,"and is willing and able n to provide approximately 40ml blood draw s at                                                                                        ",1
